AtriCure Inc.  

(Public, NASDAQ:ATRC)   Watch this stock  
Find more results for atricure
16.82
0.00 (0.00%)
Apr 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 7.55 - 23.00
Open     -
Vol / Avg. 0.00/179,674.00
Mkt cap 460.88M
P/E     -
Div/yield     -
EPS -0.56
Shares 27.40M
Beta 0.93
Inst. own 63%
May 14, 2014
AtriCure, Inc. Annual Shareholder Meeting - 9:00AM EDT - Add to calendar
Apr 24, 2014
Q1 2014 AtriCure, Inc. Earnings Conference Call - 4:30PM EDT - Add to calendar
Apr 24, 2014
Q1 2014 AtriCure, Inc. Earnings Release - 4:00PM EDT - Add to calendar
Mar 5, 2014
AtriCure, Inc. at Cowen Health Care Conference - Webcast
Feb 27, 2014
Q4 2013 AtriCure, Inc. Earnings Conference Call - Webcast
Feb 27, 2014
Q4 2013 AtriCure, Inc. Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin -22.76% -14.00%
Operating margin -22.11% -13.30%
EBITD margin - -10.83%
Return on average assets -23.56% -15.88%
Return on average equity -36.70% -26.94%
Employees 320 -
CDP Score - -

Address

6217 Centre Park Drive
WEST CHESTER, OH 45069
United States - Map
+1-513-7554107 (Phone)
+1-513-7554108 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

AtriCure, Inc. is a medical device company. The Company develops, manufactures and sells cardiac surgical ablation systems designed to create lesions, or scars, in cardiac, or heart, tissue and devices for the exclusion of the left atrial appendage. The Company has two primary product lines for the ablation of cardiac tissue. Its primary product line, which accounts for a majority of its revenues is the AtriCure Synergy Ablation System, a bipolar ablation clamp system and related radiofrequency ablation devices. It also offers a cryoablation product line, which features reusable and disposable cryoablation devices. In addition, it offers the AtriClip Gillinov-Cosgrove Left Atrial Appendage System, or AtriClip system, which is designed to exclude the left atrial appendage. In January 2014, the Company announced that it has completed the acquisition of Endoscopic Technologies, Inc. d/b/a Estech.

Officers and directors

Richard M. Johnston Independent Chairman of the Board
Age: 78
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Michael H. Carrel President, Chief Executive Officer, Director
Age: 42
Bio & Compensation  - Reuters
M Andrew Wade CPA Chief Financial Officer, Vice President
Age: 38
Bio & Compensation  - Reuters
Douglas J. Seith Senior Vice President - Sales and Marketing
Age: 47
Bio & Compensation  - Reuters
Andrew L. Lux Ph.D. Senior Vice President - R&D, Operations and QA
Age: 61
Bio & Compensation  - Reuters
Patricia J. Kennedy Vice President, General Manager - International
Age: 52
Bio & Compensation  - Reuters
Michael J. Rogge Vice President - Marketing
Bio & Compensation  - Reuters
David Francischelli Vice President - Research & Development
Bio & Compensation  - Reuters
Michael D. Hooven Director
Age: 57
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark A. Collar Independent Director
Age: 60
Bio & Compensation  - Reuters